Trial Profile
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Diazoxide (Primary)
- Indications Prader-Willi syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Essentialis; Soleno Therapeutics
- 02 Nov 2023 Results assessing the effect of 1-year administration of diazoxide choline extended-release tablet (DCCR) on hyperphagia and other complications of Prader-Willi syndrome (PWS), published in the Obesity (Silver Spring, Md.)
- 04 Oct 2023 According to a Soleno Therapeutics media release, company today announced an oral presentation at the Foundation for Prader-Willi Research (FPWR) 2023 Research Symposium, being held Oct 5-6, 2023, in Denver, Colorado. The presentation features results from withdrawal period of this recently completed C602 study for the treatment of Prader-Willi syndrome (PWS).
- 28 Sep 2023 Status changed from active, no longer recruiting to completed, according to a Soleno Therapeutics media release.